By staff writers

January 22, 2019 -- Biotechnology firm RadioMedix has received a two-year $2 million grant from the U.S. National Cancer Institute (NCI) to support the clinical development of targeted alpha-emitter therapy for neuroendocrine tumors.

The phase II Small Business Innovation Research (SBIR) grant award serves as a continuation of a successfully completed phase I SBIR grant, according to the company. Specifically, the funds will be used to support an ongoing phase I study that is assessing the safety and effectiveness of the company's AlphaMedix (lead-212 octreotate analog) agent in adults with somatostatin receptor-expressing neuroendocrine tumors, RadioMedix said. The study is currently underway at the Excel Diagnostics and Nuclear Oncology Center in Houston.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking